# Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease

Study · id `cardio:ct-nct01947790` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01947790](<https://clinicaltrials.gov/study/NCT01947790>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01947790

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT01947790. Randomized; double masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT01947790, source copy `cardio:ctgov-nct01947790-2015-08-19`, retrieved 2026-10-26)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01947790, source copy `cardio:ctgov-nct01947790-2015-08-19`, retrieved 2026-10-26)
- Primary completion: 2015-07 (actual) (ClinicalTrials.gov record NCT01947790, source copy `cardio:ctgov-nct01947790-2015-08-19`, retrieved 2026-10-26)
- Completion: 2015-07 (actual) (ClinicalTrials.gov record NCT01947790, source copy `cardio:ctgov-nct01947790-2015-08-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01947790, source copy `cardio:ctgov-nct01947790-2015-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01947790-2015-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease
- Condition: LVM
- Condition: Type 2 Diabetic Patients With IHD
- Condition: Endothelial Function
- Intervention (Drug): pioglitazone group
- Intervention (Drug): Metformin group
- Lead sponsor: Xiang Guang-da
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Xiang Guang-da (`cardio:org-xiang-guang-da`)

## Provenance

Content hash: 2dacf1a9cdda704d861ad7a7951276fd5263d62eab6ce671ac20c04442a16578
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
